Literature DB >> 23627274

Studies on novel pyridine and 2-pyridone derivatives of N-arylpiperazine as α-adrenoceptor ligands.

Marzena Baran, Elzbieta Kepczyńska, Marek Zylewski, Agata Siwek, Marek Bednarski, Marek Tadeusz Cegła1.   

Abstract

This paper describes the synthesis of a series of new N-arylpiperazine derivatives of pyridine and 2-pyridone. The in vitro pharmacological study indicated that all of the compounds possess affinity towards α1-adrenoceptors, with exception of 6d, and are selective over α2 receptor. The most potent compound 5f displayed 62-fold α2/α1 selectivity with Ki value of 27.3 nM for α1 receptor. Selectivity of other ligands ranged from 6 to more than 146-fold. Hydrochlorides of selected compounds with the best α1-adrenoceptor affinity (7b, 7e, 7f, 8b) were tested in vivo (hypotensive activity test in rats) and the results proved their α-adrenoreceptor antagonistic activity. Furthermore, the lipophilicity of the investigated compounds has been assessed experimentally and in silico.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23627274     DOI: 10.2174/0929867320999131122114922

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  3 in total

1.  Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines.

Authors:  Hong Chen; Xue Liang; Fang Xu; Bingbing Xu; Xuelan He; Biyun Huang; Mu Yuan
Journal:  Molecules       Date:  2014-08-12       Impact factor: 4.411

2.  In silico studies of piperazine derivatives as potent anti-proliferative agents against PC-3 prostate cancer cell lines.

Authors:  Fabian A Ikwu; Gideon A Shallangwa; Paul A Mamza; Adamu Uzairu
Journal:  Heliyon       Date:  2020-01-23

3.  Synthesis, bioactivity, and molecular docking of novel arylpiperazine derivatives as potential AR antagonists.

Authors:  Yueheng Qi; Hong Chen; Shijin Chen; Jianliang Shen; Jingguo Li
Journal:  Front Chem       Date:  2022-08-15       Impact factor: 5.545

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.